Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.
Purpose There are no approved treatments for recurrent/metastatic head and neck squamous cell carcinoma refractory to platinum and cetuximab. In the single-arm, phase II KEYNOTE-055 study, we evaluated pembrolizumab, an anti-programmed death 1 receptor antibody, in this platinum- and cetuximab-pretreated population with poor prognosis. Methods Eligibility stipulated disease progression within 6 months of platinum and cetuximab treatment. Patients received pembrolizumab 200 mg every 3 weeks. Imaging was performed every 6 to 9 weeks. Primary end points: overall response rate (Response Evaluation Criteria in Solid Tumors v1.1, central review) and safety. Efficacy was assessed in all dosed patients and in subgroups on the basis of programmed death ligand 1 (PD-L1) expression and human papillomavirus (HPV) status. Results Among 171 patients treated, 75% received two or more prior lines of therapy for metastatic disease, 82% were PD-L1 positive, and 22% were HPV positive. At the time of analysis, 109 patients (64%) experienced a treatment-related adverse event; 26 patients (15%) experienced a grade ≥ 3 event. Seven patients (4%) discontinued treatment, and one died of treatment-related adverse events. Overall response rate was 16% (95% CI, 11% to 23%), with a median duration of response of 8 months (range, 2+ to 12+ months); 75% of responses were ongoing at the time of analysis. Response rates were similar in all HPV and PD-L1 subgroups. Median progression-free survival was 2.1 months, and median overall survival was 8 months. Conclusion Pembrolizumab exhibited clinically meaningful antitumor activity and an acceptable safety profile in recurrent/metastatic head and neck squamous cell carcinoma previously treated with platinum and cetuximab.
Joshua Bauml, University of Pennsylvania, Philadelphia, PA; Tanguy Y. Seiwert, University of Chicago, Chicago, IL; David G. Pfister, Memorial Sloan Kettering Cancer Center, New York, NY; Francis Worden, University of Michigan Comprehensive Cancer Center, Ann Arbor; Ammar Sukari, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Stephen V. Liu, Georgetown University Hospital, Washington, DC; Jill Gilbert, Vanderbilt University School of Medicine, Nashville, TN; Nabil F. Saba, Winship Cancer Institute/Emory University, Atlanta, GA; Jared Weiss, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC; Lori Wirth, Massachusetts General Hospital; Robert Haddad, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Hyunseok Kang, Johns Hopkins University School of Medicine, Baltimore, MD; Michael K. Gibson, University Hospitals Cleveland Medical Center, Cleveland, OH; Erminia Massarelli, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven Powell, Sanford Health, Sioux Falls, SD; and Amy Meister, Xinxin Shu, and Jonathan D. Cheng, Merck & Co., Inc., Kenilworth, NJ.
Joshua
J
Bauml
Joshua Bauml, University of Pennsylvania, Philadelphia, PA; Tanguy Y. Seiwert, University of Chicago, Chicago, IL; David G. Pfister, Memorial Sloan Kettering Cancer Center, New York, NY; Francis Worden, University of Michigan Comprehensive Cancer Center, Ann Arbor; Ammar Sukari, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Stephen V. Liu, Georgetown University Hospital, Washington, DC; Jill Gilbert, Vanderbilt University School of Medicine, Nashville, TN; Nabil F. Saba, Winship Cancer Institute/Emory University, Atlanta, GA; Jared Weiss, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC; Lori Wirth, Massachusetts General Hospital; Robert Haddad, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Hyunseok Kang, Johns Hopkins University School of Medicine, Baltimore, MD; Michael K. Gibson, University Hospitals Cleveland Medical Center, Cleveland, OH; Erminia Massarelli, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven Powell, Sanford Health, Sioux Falls, SD; and Amy Meister, Xinxin Shu, and Jonathan D. Cheng, Merck & Co., Inc., Kenilworth, NJ.
Tanguy Y
TY
Seiwert
Joshua Bauml, University of Pennsylvania, Philadelphia, PA; Tanguy Y. Seiwert, University of Chicago, Chicago, IL; David G. Pfister, Memorial Sloan Kettering Cancer Center, New York, NY; Francis Worden, University of Michigan Comprehensive Cancer Center, Ann Arbor; Ammar Sukari, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Stephen V. Liu, Georgetown University Hospital, Washington, DC; Jill Gilbert, Vanderbilt University School of Medicine, Nashville, TN; Nabil F. Saba, Winship Cancer Institute/Emory University, Atlanta, GA; Jared Weiss, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC; Lori Wirth, Massachusetts General Hospital; Robert Haddad, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Hyunseok Kang, Johns Hopkins University School of Medicine, Baltimore, MD; Michael K. Gibson, University Hospitals Cleveland Medical Center, Cleveland, OH; Erminia Massarelli, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven Powell, Sanford Health, Sioux Falls, SD; and Amy Meister, Xinxin Shu, and Jonathan D. Cheng, Merck & Co., Inc., Kenilworth, NJ.
David G
DG
Pfister
Joshua Bauml, University of Pennsylvania, Philadelphia, PA; Tanguy Y. Seiwert, University of Chicago, Chicago, IL; David G. Pfister, Memorial Sloan Kettering Cancer Center, New York, NY; Francis Worden, University of Michigan Comprehensive Cancer Center, Ann Arbor; Ammar Sukari, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Stephen V. Liu, Georgetown University Hospital, Washington, DC; Jill Gilbert, Vanderbilt University School of Medicine, Nashville, TN; Nabil F. Saba, Winship Cancer Institute/Emory University, Atlanta, GA; Jared Weiss, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC; Lori Wirth, Massachusetts General Hospital; Robert Haddad, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Hyunseok Kang, Johns Hopkins University School of Medicine, Baltimore, MD; Michael K. Gibson, University Hospitals Cleveland Medical Center, Cleveland, OH; Erminia Massarelli, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven Powell, Sanford Health, Sioux Falls, SD; and Amy Meister, Xinxin Shu, and Jonathan D. Cheng, Merck & Co., Inc., Kenilworth, NJ.
Francis
F
Worden
Joshua Bauml, University of Pennsylvania, Philadelphia, PA; Tanguy Y. Seiwert, University of Chicago, Chicago, IL; David G. Pfister, Memorial Sloan Kettering Cancer Center, New York, NY; Francis Worden, University of Michigan Comprehensive Cancer Center, Ann Arbor; Ammar Sukari, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Stephen V. Liu, Georgetown University Hospital, Washington, DC; Jill Gilbert, Vanderbilt University School of Medicine, Nashville, TN; Nabil F. Saba, Winship Cancer Institute/Emory University, Atlanta, GA; Jared Weiss, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC; Lori Wirth, Massachusetts General Hospital; Robert Haddad, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Hyunseok Kang, Johns Hopkins University School of Medicine, Baltimore, MD; Michael K. Gibson, University Hospitals Cleveland Medical Center, Cleveland, OH; Erminia Massarelli, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven Powell, Sanford Health, Sioux Falls, SD; and Amy Meister, Xinxin Shu, and Jonathan D. Cheng, Merck & Co., Inc., Kenilworth, NJ.
Stephen V
SV
Liu
Joshua Bauml, University of Pennsylvania, Philadelphia, PA; Tanguy Y. Seiwert, University of Chicago, Chicago, IL; David G. Pfister, Memorial Sloan Kettering Cancer Center, New York, NY; Francis Worden, University of Michigan Comprehensive Cancer Center, Ann Arbor; Ammar Sukari, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Stephen V. Liu, Georgetown University Hospital, Washington, DC; Jill Gilbert, Vanderbilt University School of Medicine, Nashville, TN; Nabil F. Saba, Winship Cancer Institute/Emory University, Atlanta, GA; Jared Weiss, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC; Lori Wirth, Massachusetts General Hospital; Robert Haddad, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Hyunseok Kang, Johns Hopkins University School of Medicine, Baltimore, MD; Michael K. Gibson, University Hospitals Cleveland Medical Center, Cleveland, OH; Erminia Massarelli, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven Powell, Sanford Health, Sioux Falls, SD; and Amy Meister, Xinxin Shu, and Jonathan D. Cheng, Merck & Co., Inc., Kenilworth, NJ.
Jill
J
Gilbert
Joshua Bauml, University of Pennsylvania, Philadelphia, PA; Tanguy Y. Seiwert, University of Chicago, Chicago, IL; David G. Pfister, Memorial Sloan Kettering Cancer Center, New York, NY; Francis Worden, University of Michigan Comprehensive Cancer Center, Ann Arbor; Ammar Sukari, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Stephen V. Liu, Georgetown University Hospital, Washington, DC; Jill Gilbert, Vanderbilt University School of Medicine, Nashville, TN; Nabil F. Saba, Winship Cancer Institute/Emory University, Atlanta, GA; Jared Weiss, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC; Lori Wirth, Massachusetts General Hospital; Robert Haddad, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Hyunseok Kang, Johns Hopkins University School of Medicine, Baltimore, MD; Michael K. Gibson, University Hospitals Cleveland Medical Center, Cleveland, OH; Erminia Massarelli, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven Powell, Sanford Health, Sioux Falls, SD; and Amy Meister, Xinxin Shu, and Jonathan D. Cheng, Merck & Co., Inc., Kenilworth, NJ.
Nabil F
NF
Saba
Joshua Bauml, University of Pennsylvania, Philadelphia, PA; Tanguy Y. Seiwert, University of Chicago, Chicago, IL; David G. Pfister, Memorial Sloan Kettering Cancer Center, New York, NY; Francis Worden, University of Michigan Comprehensive Cancer Center, Ann Arbor; Ammar Sukari, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Stephen V. Liu, Georgetown University Hospital, Washington, DC; Jill Gilbert, Vanderbilt University School of Medicine, Nashville, TN; Nabil F. Saba, Winship Cancer Institute/Emory University, Atlanta, GA; Jared Weiss, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC; Lori Wirth, Massachusetts General Hospital; Robert Haddad, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Hyunseok Kang, Johns Hopkins University School of Medicine, Baltimore, MD; Michael K. Gibson, University Hospitals Cleveland Medical Center, Cleveland, OH; Erminia Massarelli, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven Powell, Sanford Health, Sioux Falls, SD; and Amy Meister, Xinxin Shu, and Jonathan D. Cheng, Merck & Co., Inc., Kenilworth, NJ.
Jared
J
Weiss
Joshua Bauml, University of Pennsylvania, Philadelphia, PA; Tanguy Y. Seiwert, University of Chicago, Chicago, IL; David G. Pfister, Memorial Sloan Kettering Cancer Center, New York, NY; Francis Worden, University of Michigan Comprehensive Cancer Center, Ann Arbor; Ammar Sukari, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Stephen V. Liu, Georgetown University Hospital, Washington, DC; Jill Gilbert, Vanderbilt University School of Medicine, Nashville, TN; Nabil F. Saba, Winship Cancer Institute/Emory University, Atlanta, GA; Jared Weiss, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC; Lori Wirth, Massachusetts General Hospital; Robert Haddad, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Hyunseok Kang, Johns Hopkins University School of Medicine, Baltimore, MD; Michael K. Gibson, University Hospitals Cleveland Medical Center, Cleveland, OH; Erminia Massarelli, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven Powell, Sanford Health, Sioux Falls, SD; and Amy Meister, Xinxin Shu, and Jonathan D. Cheng, Merck & Co., Inc., Kenilworth, NJ.
Lori
L
Wirth
Joshua Bauml, University of Pennsylvania, Philadelphia, PA; Tanguy Y. Seiwert, University of Chicago, Chicago, IL; David G. Pfister, Memorial Sloan Kettering Cancer Center, New York, NY; Francis Worden, University of Michigan Comprehensive Cancer Center, Ann Arbor; Ammar Sukari, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Stephen V. Liu, Georgetown University Hospital, Washington, DC; Jill Gilbert, Vanderbilt University School of Medicine, Nashville, TN; Nabil F. Saba, Winship Cancer Institute/Emory University, Atlanta, GA; Jared Weiss, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC; Lori Wirth, Massachusetts General Hospital; Robert Haddad, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Hyunseok Kang, Johns Hopkins University School of Medicine, Baltimore, MD; Michael K. Gibson, University Hospitals Cleveland Medical Center, Cleveland, OH; Erminia Massarelli, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven Powell, Sanford Health, Sioux Falls, SD; and Amy Meister, Xinxin Shu, and Jonathan D. Cheng, Merck & Co., Inc., Kenilworth, NJ.
Ammar
A
Sukari
Joshua Bauml, University of Pennsylvania, Philadelphia, PA; Tanguy Y. Seiwert, University of Chicago, Chicago, IL; David G. Pfister, Memorial Sloan Kettering Cancer Center, New York, NY; Francis Worden, University of Michigan Comprehensive Cancer Center, Ann Arbor; Ammar Sukari, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Stephen V. Liu, Georgetown University Hospital, Washington, DC; Jill Gilbert, Vanderbilt University School of Medicine, Nashville, TN; Nabil F. Saba, Winship Cancer Institute/Emory University, Atlanta, GA; Jared Weiss, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC; Lori Wirth, Massachusetts General Hospital; Robert Haddad, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Hyunseok Kang, Johns Hopkins University School of Medicine, Baltimore, MD; Michael K. Gibson, University Hospitals Cleveland Medical Center, Cleveland, OH; Erminia Massarelli, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven Powell, Sanford Health, Sioux Falls, SD; and Amy Meister, Xinxin Shu, and Jonathan D. Cheng, Merck & Co., Inc., Kenilworth, NJ.
Hyunseok
H
Kang
Joshua Bauml, University of Pennsylvania, Philadelphia, PA; Tanguy Y. Seiwert, University of Chicago, Chicago, IL; David G. Pfister, Memorial Sloan Kettering Cancer Center, New York, NY; Francis Worden, University of Michigan Comprehensive Cancer Center, Ann Arbor; Ammar Sukari, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Stephen V. Liu, Georgetown University Hospital, Washington, DC; Jill Gilbert, Vanderbilt University School of Medicine, Nashville, TN; Nabil F. Saba, Winship Cancer Institute/Emory University, Atlanta, GA; Jared Weiss, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC; Lori Wirth, Massachusetts General Hospital; Robert Haddad, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Hyunseok Kang, Johns Hopkins University School of Medicine, Baltimore, MD; Michael K. Gibson, University Hospitals Cleveland Medical Center, Cleveland, OH; Erminia Massarelli, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven Powell, Sanford Health, Sioux Falls, SD; and Amy Meister, Xinxin Shu, and Jonathan D. Cheng, Merck & Co., Inc., Kenilworth, NJ.
Michael K
MK
Gibson
Joshua Bauml, University of Pennsylvania, Philadelphia, PA; Tanguy Y. Seiwert, University of Chicago, Chicago, IL; David G. Pfister, Memorial Sloan Kettering Cancer Center, New York, NY; Francis Worden, University of Michigan Comprehensive Cancer Center, Ann Arbor; Ammar Sukari, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Stephen V. Liu, Georgetown University Hospital, Washington, DC; Jill Gilbert, Vanderbilt University School of Medicine, Nashville, TN; Nabil F. Saba, Winship Cancer Institute/Emory University, Atlanta, GA; Jared Weiss, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC; Lori Wirth, Massachusetts General Hospital; Robert Haddad, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Hyunseok Kang, Johns Hopkins University School of Medicine, Baltimore, MD; Michael K. Gibson, University Hospitals Cleveland Medical Center, Cleveland, OH; Erminia Massarelli, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven Powell, Sanford Health, Sioux Falls, SD; and Amy Meister, Xinxin Shu, and Jonathan D. Cheng, Merck & Co., Inc., Kenilworth, NJ.
Erminia
E
Massarelli
Joshua Bauml, University of Pennsylvania, Philadelphia, PA; Tanguy Y. Seiwert, University of Chicago, Chicago, IL; David G. Pfister, Memorial Sloan Kettering Cancer Center, New York, NY; Francis Worden, University of Michigan Comprehensive Cancer Center, Ann Arbor; Ammar Sukari, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Stephen V. Liu, Georgetown University Hospital, Washington, DC; Jill Gilbert, Vanderbilt University School of Medicine, Nashville, TN; Nabil F. Saba, Winship Cancer Institute/Emory University, Atlanta, GA; Jared Weiss, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC; Lori Wirth, Massachusetts General Hospital; Robert Haddad, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Hyunseok Kang, Johns Hopkins University School of Medicine, Baltimore, MD; Michael K. Gibson, University Hospitals Cleveland Medical Center, Cleveland, OH; Erminia Massarelli, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven Powell, Sanford Health, Sioux Falls, SD; and Amy Meister, Xinxin Shu, and Jonathan D. Cheng, Merck & Co., Inc., Kenilworth, NJ.
Steven
S
Powell
Joshua Bauml, University of Pennsylvania, Philadelphia, PA; Tanguy Y. Seiwert, University of Chicago, Chicago, IL; David G. Pfister, Memorial Sloan Kettering Cancer Center, New York, NY; Francis Worden, University of Michigan Comprehensive Cancer Center, Ann Arbor; Ammar Sukari, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Stephen V. Liu, Georgetown University Hospital, Washington, DC; Jill Gilbert, Vanderbilt University School of Medicine, Nashville, TN; Nabil F. Saba, Winship Cancer Institute/Emory University, Atlanta, GA; Jared Weiss, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC; Lori Wirth, Massachusetts General Hospital; Robert Haddad, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Hyunseok Kang, Johns Hopkins University School of Medicine, Baltimore, MD; Michael K. Gibson, University Hospitals Cleveland Medical Center, Cleveland, OH; Erminia Massarelli, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven Powell, Sanford Health, Sioux Falls, SD; and Amy Meister, Xinxin Shu, and Jonathan D. Cheng, Merck & Co., Inc., Kenilworth, NJ.
Amy
A
Meister
Joshua Bauml, University of Pennsylvania, Philadelphia, PA; Tanguy Y. Seiwert, University of Chicago, Chicago, IL; David G. Pfister, Memorial Sloan Kettering Cancer Center, New York, NY; Francis Worden, University of Michigan Comprehensive Cancer Center, Ann Arbor; Ammar Sukari, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Stephen V. Liu, Georgetown University Hospital, Washington, DC; Jill Gilbert, Vanderbilt University School of Medicine, Nashville, TN; Nabil F. Saba, Winship Cancer Institute/Emory University, Atlanta, GA; Jared Weiss, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC; Lori Wirth, Massachusetts General Hospital; Robert Haddad, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Hyunseok Kang, Johns Hopkins University School of Medicine, Baltimore, MD; Michael K. Gibson, University Hospitals Cleveland Medical Center, Cleveland, OH; Erminia Massarelli, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven Powell, Sanford Health, Sioux Falls, SD; and Amy Meister, Xinxin Shu, and Jonathan D. Cheng, Merck & Co., Inc., Kenilworth, NJ.
Xinxin
X
Shu
Joshua Bauml, University of Pennsylvania, Philadelphia, PA; Tanguy Y. Seiwert, University of Chicago, Chicago, IL; David G. Pfister, Memorial Sloan Kettering Cancer Center, New York, NY; Francis Worden, University of Michigan Comprehensive Cancer Center, Ann Arbor; Ammar Sukari, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Stephen V. Liu, Georgetown University Hospital, Washington, DC; Jill Gilbert, Vanderbilt University School of Medicine, Nashville, TN; Nabil F. Saba, Winship Cancer Institute/Emory University, Atlanta, GA; Jared Weiss, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC; Lori Wirth, Massachusetts General Hospital; Robert Haddad, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Hyunseok Kang, Johns Hopkins University School of Medicine, Baltimore, MD; Michael K. Gibson, University Hospitals Cleveland Medical Center, Cleveland, OH; Erminia Massarelli, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven Powell, Sanford Health, Sioux Falls, SD; and Amy Meister, Xinxin Shu, and Jonathan D. Cheng, Merck & Co., Inc., Kenilworth, NJ.
Jonathan D
JD
Cheng
Joshua Bauml, University of Pennsylvania, Philadelphia, PA; Tanguy Y. Seiwert, University of Chicago, Chicago, IL; David G. Pfister, Memorial Sloan Kettering Cancer Center, New York, NY; Francis Worden, University of Michigan Comprehensive Cancer Center, Ann Arbor; Ammar Sukari, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Stephen V. Liu, Georgetown University Hospital, Washington, DC; Jill Gilbert, Vanderbilt University School of Medicine, Nashville, TN; Nabil F. Saba, Winship Cancer Institute/Emory University, Atlanta, GA; Jared Weiss, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC; Lori Wirth, Massachusetts General Hospital; Robert Haddad, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Hyunseok Kang, Johns Hopkins University School of Medicine, Baltimore, MD; Michael K. Gibson, University Hospitals Cleveland Medical Center, Cleveland, OH; Erminia Massarelli, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven Powell, Sanford Health, Sioux Falls, SD; and Amy Meister, Xinxin Shu, and Jonathan D. Cheng, Merck & Co., Inc., Kenilworth, NJ.
Robert
R
Haddad
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D060890:B7-H1 Antigen / Q000032:analysis*; D002294:Carcinoma, Squamous Cell / Q000737:chemistry / Q000188:drug therapy* / Q000556:secondary / Q000821:virology; D000068818:Cetuximab / Q000627:therapeutic use; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006258:Head and Neck Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D030361:Papillomavirus Infections / Q000150:complications; D017671:Platinum Compounds / Q000627:therapeutic use; D066066:Response Evaluation Criteria in Solid Tumors; D019233:Retreatment; D015996:Survival Rate
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D060890:B7-H1 Antigen; C423236:CD274 protein, human; D017671:Platinum Compounds; C582435:pembrolizumab; D000068818:Cetuximab